We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 10, 2021

Long-Term Outcomes in Patients With Advanced NSCLC Who Completed 2 Years of ICI or Achieved a Durable Response After Discontinuation Without Disease Progression

Cancer

 

Additional Info

Cancer
Long-Term Outcomes in Patients With Advanced and/or Metastatic Non-Small Cell Lung Cancer who Completed 2 Years of Immune Checkpoint Inhibitors or Achieved a Durable Response After Discontinuation Without Disease Progression: Multicenter, Real-World Data (KCSG LU20-11)
Cancer 2021 Oct 27;[EPub Ahead of Print], H Kim, DW Kim, M Kim, Y Lee, HK Ahn, JH Cho, IH Kim, YG Lee, SH Shin, SE Park, J Jung, EJ Kang, MJ Ahn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading